OPEX® and Peltier Partner to Deliver First-of-Its-Kind Cold Storage Solution for Automated Fulfillment Systems
20.1.2026 15:00:00 CET | Business Wire | Press Release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, today announced a strategic technology partnership with Peltier, an innovator in cold chain commerce, to offer a first-of-its-kind, multi-temperature zone, multi-deep cold storage solution for automated fulfillment systems. This collaboration introduces advanced multi-temperature capabilities to OPEX Corporation’s industry-leading Perfect Pick® and Infinity® automated storage and retrieval systems (ASRS), empowering customers in the grocery, pharmaceutical, and life sciences markets to seamlessly store and retrieve chilled and frozen products utilizing Peltier’s actively cooled, AI-enabled totes, eliminating the need for costly freezer chambers or specialized infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120776429/en/
OPEX iBOTs efficiently transport and present Peltier chilled (light blue) and frozen (dark blue) totes at the pick station of the Perfect Pick ASRS.
“Many of our customers have expressed a need for multi-temperature capabilities, but are often dissuaded by traditional solutions that require costly infrastructure and complex system changes,” said Monty McVaugh, Head of Product, Warehouse Automation, OPEX. “By integrating Peltier’s tote technology into our existing framework, we can now deliver a flexible, scalable, efficient, and highly cost-effective solution without modifying our core systems.”
The Peltier ToteTM is designed with precise, individually controlled temperature setpoints and IoT connectivity, enabling real-time monitoring and management of storage conditions through integrated API messages. Power is provided to each tote while in multi-deep storage, and temperatures are maintained during transport by OPEX iBOT® robotic vehicles, ensuring continuous cold chain integrity. This groundbreaking innovation allows organizations to integrate refrigerated and frozen inventory directly into ambient warehouse environments, markedly simplifying operations and maximizing space utilization, while reducing capital expenditures.
Furthermore, this approach to cold storage enhances worker comfort and safety by eliminating the need for staff to operate in harsh freezer environments. The system’s physical AI capabilities drive dynamic energy management, and provide detailed reporting for sensitive products, including those subject to strict FDA regulations. Unlike conventional cold storage rooms, where refrigeration failure can result in total product loss, Peltier Totes isolate any potential issues to individual totes, minimizing both risk and waste. The totes are also environmentally friendly, powered by patented solid state cooling technology, as opposed to compressor based refrigeration systems that use harmful refrigerants.
“The Peltier Tote is fundamentally changing how the world applies cold storage in commerce,” said Hanson Li, Chief Executive Officer, Peltier. “Together, OPEX and Peltier are delivering an advanced solution that breaks the traditional paradigm, where cold and temperature were treated as major constraints. Customers can now optimize operations, processes, and space without these concerns. We’re very proud to be partnering with OPEX to offer a consequential solution to what has been a longstanding challenge for so many.”
About OPEX® Corporation
OPEX® Corporation is a global leader in Next Generation Automation, providing innovative, unique solutions for warehouse, document and mail automation. With headquarters in Moorestown, NJ—and facilities in Pennsauken, NJ; Plano, TX; France; Germany; Switzerland; the United Kingdom; and Australia—OPEX has nearly 1,600 employees who are continuously reimagining and delivering customized, scalable technology solutions that solve the business challenges of today and in the future. For more information, visit opex.com.
About Peltier
Peltier is redefining the cold chain industry by powering active, connected, and precise solutions built for the future of commerce. Peltier’s Modular Cold Chain (MC²) is the world’s first scalable, solid-state cooling ecosystem. The modular and IoT-enabled Peltier ToteTM, deployed in a variety of Peltier FrameworkTM (manual, automated and last mile), protects vulnerable aspects of the cold chain with flexibility and intelligence. The Peltier CloudTM enables physical AI to enhance critical operations while delivering energy management not possible before. Peltier’s vision is to master the art of cold to improve how we work and live. For more information, visit peltierpro.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260120776429/en/
Contacts
Media Contacts
For OPEX Corporation
Laura Evans
levans@opex.com
+1.856.727.1100 x 5012
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom